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Summary Thirty patients with hypercalcaemia due to malignancy that persisted following rehydration, were
treated with a single dose of the bisphosphonate, clodronate. Clodronate (1.5 g) was administered int-
ravenously in 500 ml normal saline over 4 h. Serum and urine biochemistry were measured before and after
treatment and the results were compared with data from 15 patients given the recommended regimen 300 mg
intravenous clodronate daily for 5 consecutive days.
The single infusion induced a rapid and significant fall in serum calcium, apparent at day 3 (P<0.0001)
that persisted to the end of follow-up at day 10 (P<0.001). Eighty per cent (24/30) of patients became
normocalcaemic. The response was associated with a significant decrease in fasting urinary calcium excretion,
and no change in renal function, as judged by serum creatinine. The same dose of clodronate, given as 5 daily
infusions, induced a comparable decrease in serum calcium, but was less rapid in onset so that at day 3 the
serum calcium was significantly lower with the single infusion (P = 0.02). The calcium lowering effect of both
regimens depended on the tumour type.
We conclude that the single infusion of 1500 mg clodronate is as effective in reducing serum calcium as the
same dose given over 5 days. The single infusion has a more rapid onset of effect, is more convenient than
multiple infusions, and has no adverse effect on renal function.
The majority of cases of hypercalcaemia due to malignant
disease are associated with focal osteolysis in the proximity
of skeletal metastases, but several other factors also con-
tribute to the development or maintenance of hypercalcaemia
(Mundy et al., 1984; Percival et al., 1985). A minority of
patients with solid tumours have hypercalcaemia in the
absence of skeletal metastases but humoral factors may be
found both in the presence and absence of osteolytic disease.
This humoral hypercalcaemia of malignancy is attributed to
the production by the tumour of endocrine factors. Of these
there is increasing evidence that parathyroid hormone related
peptide (PTHrP) plays a major role (Martin et al., 1988). The
amino terminal of this peptide shows homology with
parathyroid hormone and both peptides appear to be equi-
potent in most test systems. In humoral hypercalcaemia
PTHrP promotes renal tubular reabsorption of calcium and,
like parathyroid hormone, it also contributes to increased
bone resorption (Yates et al., 1988). Both the renal and bone
effects predispose to the development of hypercalcaemia. The
haematological malignancies are a less common cause of
hypercalcaemia than solid tumours but myeloma, in partic-
ular, is associated with accelerated osteolysis and disturbed
calcium metabolism.
Focal or generalised osteolysis is the common link between
the different mechanisms of hypercalcaemia in malignancy. It
is believed to be mediated in large part, if not exclusively, by
increased osteoclast activity (Bonjour & Rizzoli, 1989). This
has provided the rationale for the use of bisphosphonates in
the treatment of hypercalcaemia of malignancy. Bisphos-
phonates are specific inhibitors of osteoclast mediated bone
resorption and, in combination with intravascular volume
expansion, have now become first line of treatment for malig-
nant hypercalcaemia (Bonjour et al., 1984). The three agents
widely used are pamidronate (aminopropylidene bisphos-
phonate) (Coleman & Rubens, 1987), clodronate (dichloro-
methylene bisphosphonate) (Kanis et al., 1991) and etidronate(Singer et al., 1991). Although all have been shown to be
effective in the acute management of hypercalcaemia, there
are some differences in the responses to treatment. The effects
of intravenous etidronate on serum calcium are incomplete
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(Kanis et al., 1987; Singer et al., 1991) and the oral formula-
tion is less effective in inhibiting bone resorption. Moreover,
both oral and intravenous etidronate impair the mineralisa-
tion of bone as well as its resorption (Preston et al., 1986;
Russell et al., 1974; Kanis et al., 1987), so that this agent is
unsuitable for continuous long-term use.
Neither clodronate nor pamidronate impair the mineralisa-
tion of bone at the doses used to treat hypercalcaemia
(Thiebaud et al., 1991; Elomaa et al., 1987). Pamidronate is
more potent than clodronate on a molar basis and is effective
when given as a single infusion of 30-45 mg given over 4 h,
but causes transient lymphopenia and post-infusion pyrexia
in a minority of patients (Morton et al., 1989). Additional
unwanted effects include symptomatic hypocalcaemia, rigors,
malaise, thrombophlebitis and oliguria (Gallacher et al.,
1989). On the other hand the single infusion is convenient for
out-patient treatment, but hypercalcaemia recurs. Oral
pamidronate has been shown to maintain normocalcaemia
but is not presently available because of gastrointestinal side
effects (van Holten-Verzantvoort et al., 1987).
Clodronate has fewer side effects and can be given both
intravenously and by mouth (Kanis et al., 1990; Bonjour &
Rizzoli, 1991). The recommended intravenous regimen of
clodronate is up to 5 separate infusions of 300 mg given on
consecutive days, which is less convenient than treatment
with a single infusion. A single infusion of 600 mg seems to
give worthwhile response but the effects are less complete
than with pamidronate (Ralston et al., 1989), perhaps due to
the suboptimal dose of clodronate used (Kanis et al., 1990).
This suggested that a single infusion of a higher dose of
clodronate might induce a more complete response and com-
bine the convenience of a single treatment regimen with few
unwanted effects.
This paper reports our experience over 12 months of giving
clodronate as a single 1500 mg infusion over 4 h, and com-
pares the results with retrospective data from patients treated
with the conventional 5 day regime of 300mg daily.
Materials and methods
Between May 1990 and May 1991 30 patients (13 women
and 17 men) with tumour-induced hypercalcaemia were
treated with a single intravenous infusion of clodronate. A
total of 40 treatments were given as seven patients were
treated more than one (Table I). The mean age of the
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Table I Details of patients studied according to tumour type
Tumour type Number of treatments Number ofpatients
Breast 14 9
Lung 9 6
Myeloma 6 5
Bladder 2 2
Unknown primary 2 2
Hypernephroma 1 I
Cervix 2 1
Ovary 1 I
Oesophagus I I
Melanoma 1 1
Pancreas 1 1
patients was 57.6 years (range 34-72). Thirteen patients had
bone metastases as judged by skeletal scintigraphy and
radiography, five had myeloma and 12 had solid tumours
with hypercalcaemia in the absence of bone metastases.
Patients were studied if hypercalcaemia (adjusted serum
calcium > 2.63 mmol 1- 1) persisted following 48 h of extra-
cellular volume expansion with normal saline 3 litres daily.
The patients were then treated with 1500 mg clodronate given
in 500 ml normal saline and infused intravenously over 4 h.
Saline infusions were continued thereafter, but stopped if the
serum calcium concentration fell to within normal limits.
Those patients with normal serum calcium at day 7 were
given clodronate 1600 mg daily by mouth as maintenance
therapy. The five patients with myeloma were treated with
chemotherapy within a week of clodronate infusion. No
other patient had concomitant chemotherapy, but three of
the patients with solid tumours had radiotherapy given dur-
ing the study.
Venous blood samples were taken at study entry (day
- 2), on the day of treatment (day 0) and at 3, 5, 7 and 10
days for measurement of serum calcium, albumin and serum
creatinine using a Technicon SMAC. Total serum calcium
values were adjusted for fluctuations in albumin concentra-
tion (Kanis & Yates, 1985). A 2 h fasting urine sample was
taken at day 0 and between days 5-7 for the measurement of
calcium and creatinine. Fasting calcium excretion was ex-
pressed as a ratio to creatine excretion.
The results of this study were compared with data from 15
hypercalcaemic patients treated in 1988-89 (Kanis et al.,
1990); 1 1 women and four men. The mean age was 53.7 years
with a range of 17-78 years. There was a similar distribution
of tumour type: six patients had bone metastases from solid
tumours, four had myeloma and five had humoral hypercal-
caemia without evidence of skeletal metastases. The criteria
for study were identical. Serum calcium was measured at day
- 2 and at day 0 the patients were treated with an intra-
venous infusion of clodronate 300 mg in 500 ml normal
saline over 4 h. This treatment was repeated for 5 consecutive
days (days 1-5). Adjusted serum calcium and serum
creatinine were measured at days - 2, 0, 3, 5, 7 and again at
2 weeks. Fasting urine samples were taken at days 0 and 7
and analysed for calcium and creatinine. No concomitant
treatment was given during the 2 week follow-up period.
Paired t-tests were used to compare mean values before
and after treatment. The non-paired t-test was used to com-
pare the two treatments. Results are expressed as the
mean ± standard error of the mean.
Results
Single infusion
Mean serum calcium values fell from 3.27 ± 0.09 mmol 1I
before treatment to 2.65 ± 0.06 mmol 1` after 3 days (P<
0.001), reaching a nadir at 5 days (2.60 ± 0.08; P<0.001).
Mean values begap to rise after day 7 (Figure 1), and at day
10 was significantly higher than the mean value at day 5
(P = 0.02) but remained significantly lower than before treat-
ment (P< 0.001).
Serum calcium fell to normal (2.12-2.63 mmol I') in the
majority (54%) by day 3 and became normal within 7 days
in 24 of the 30 patients (80%) following the first treatment.
In the ten repeated treatments the serum calcium fell to
normal in 71% after both the initial treatment and re-
treatment, suggesting that they remained sensitive to clo-
dronato treatment despite recurrence of hypercalcaemia. In
the two patients who did not become normocalcaemic with
retreatment, the response to the first treatment was also
incomplete.
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Figure 1 Serum calcium (mean + s.e.m.) in 40 treatments using a single infusion of clodronate 1500 mg (-) and in 15 treatments
using clodronate 300 mg gaily for 5 days (-). Asterisks denote the significance of differences from pretreatment values (*P <0.01;
**P<0.001; ***P<0.0001).
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Table II Biochemical responses (mean + s.e.m.) in 30 treatments using a single infusion of
clodronate 1500 mg and in 15 treatments using clodronate 300 mg daily for 5 days
Single infusion Multiple infusions
DayO DayS DayO DayS
Serum calcium (mmol 1-l) 3.27 + 0.09 2.60 + 0.08a 3.41 + 0.14 2.54 + 0.09a
Urine calcium 1.51 + 0.19 0.65 + 0.15a 1.93 + 0.24 0.68 + 0.17a
(mmol mmol- ' creatinine)
Serum creatinine (.Lmol 1-') 139 + 21 135 + 20
aDenotes the significance of changes during treatment (P< 0.001). There were no significant
differences at day 0 or at day 5 between the two treatment regimens.
Table III The number of patients studied (n) and the proportion of patients (%) becoming
normocalcaemic within 7 days of treatment with the two regimens of intravenous
clodronate
Single infusion Multiple infusions Either treatment
n % n % n %
Humoral hypercalcaemia 12a 75 5 40 17 65
without skeletal metastases
Skeletal metastases 13 77 6 67 19 74
Myelomatosis 5 100 4 100 9 100
All patients 30 80 15 67 45 76
aThree patients had concomitant radiotherapy treatment.
The fall in serum calcium was associated with a significant
decrease in the fasting urinary excretion of calcium which fell
to 43% of its original value (P<0.001; Table II).
The proportion of patients becoming normocalcaemic
varied according to tumour type (Table III). All patients with
myeloma became normocalcaemic compared with 75% of
patients with humoral hypercalcaemia without skeletal metas-
tases and 77% of patients with focal bone metastases.
Two patients had mild asymptomatic hypocalcaemia
(serum calcium 2.01 and 2.06 mmol l-) which reversed when
treatment stopped. White cell counts did not change except
in five of the six patients given chemotherapy where these
fell. No side effects were reported and there was no
significant change in mean serum creatinine (Table II).
Five daily infusions
There was no significant difference in mean serum calcium
values between these patients and those given the single
infusion. Nor was there a difference in the distribution of
those with mild or marked hypercalcaemia (73 and 74%
above 3.00 mmol '-').
With the consecutive daily infusions mean serum calcium
values fell significantly following the start of treatment from
3.41 ± 0.14 mmol 1 to 2.95 ± 0.13 after 3 days, 2.54 ± 0.09 at
5 days, 2.56 ± 0.16 at 7 days and 2.61 ± 0.09 mmol 1 at 14
days (Figure 1). The onset of effect was slower than with the
single infusion. At day 0 there was no significant difference
between mean serum calcium values in the two different
treatment groups, but at day 3 the patients given the single
infusion showed a significantly greater change in serum cal-
cium values than those given consecutive infusions (P =
0.02). There was no significant difference between the two
groups from day 5 onwards.
Treatment was associated with a significant decrease in
mean fasting urinary calcium which fell to 35% of its
pretreatment value (P = 0.0001, Table II). The degree of
suppression of calcium excretion did not differ significantly
from that seen after the single infusion.
The proportion of patients becoming normocalcaemic after
treatment wsa 67%, as compared to 80% in the single
infusion group (NS). As in the case of the single infusion, all
of the patients with myeloma became normocalcaemic, but
this occurred in only 67% of patients with focal bone metas-
tases and 40% of those with humoral hypercalcaemia
without skeletal metastases. One patient developed mild
asymptomatic hypocalcaemia (2.09 mmol l') at day 5 which
resolved thereafter.
Discussion
This study confirms the efficacy of intravenous clodronate in
the treatment of malignant hypercalcaemia (Zeigler &
Scharla, 1989; Urwin et al., 1987). The marked decrease in
fasting urinary calcium excretion indicates that the calcium
lowering action of clodronate is attributable to inhibition of
bone resorption rather than to continued extracellular
volume expansion.
Although we have used historical controls, the single
infusion treatment appeared to be at least as effective as the
recommended regimen using the same total dose but given
over five consecutive days. There was no significant difference
between the two regimens in the adjusted serum calcium or
the urinary calcium excretion before treatment or at the end
of follow-up. Thus, there was little difference in the com-
pleteness of the response but this appeared to be more rapid
following the single infusion than with the multiple dose
regimen. Serum calcium values rose at day 10 in those
patients receiving the single infusion, though the change was
not significant. In contrast, mean values remained within the
reference range at the 14th day of observation (Figure 1). It
would be unwise to conclude that the single infusion resulted
in a more rapid relapse since this may depend on the time
since the last exposure to clodronate, but this remains a
possibility.
The proportion of patients becoming normocalcaemic fol-
lowing treatment was similar to that previously reported for
repeated daily infusions of clodronate (Kanis et al., 1990;
Zeigler & Scharla, 1989), but greater than that reported for
single infusions of clondronate where lower doses were used
(Ralston et al., 1989). This strengthens the view that the dose
used in these studies was suboptimal (Kanis et al., 1990).
The proportion of patients becoming normocalcaemic was
greater in the patients given the single infusion (80%) than in
patients given the standard 5 day regimen (67%), but not
significantly so. In any case it is not suggested that the
response rate was different, since the response depended also
on the tumour type. The analysis of response according to
tumour type is based on small numbers but nonetheless
confirms that the response to clodronate varies according to
the contribution of bone resorption to the hypercalcaemic
state (Bonjour et al., 1988; Kanis et al., 1990). This is consis-
tent with the knowledge that the calcium lowering effect of
the bisphosphonates is due to the inhibition of bone resorp-
tion and that the response to bisphosphonates depends upon
the degree with which increased bone resorption contributes
to the hypercalcaemic state.
CLODRONATE IN MALIGNANT HYPERCALCAEMIA 563
All patients with myeloma became normocalcaemic but the
response rate was less in patients with bone metastases (77%
in the single infusion group and 67% in the daily infusion
group). Previous studies have shown that a significant
minority of patients have increased renal tubular reabsorp-
tion of calcium which contributes to the maintenance of
hypercalcaemia (Percival et al., 1985). In the humoral hyper-
calcaemia of malignancy, increased renal tubular reabsorp-
tion of calcium commonly contributes to the maintenance of
hypercalcaemia (Stewart et al., 1980) and bisphosphonates
induce an incomplete response despite the suppression of
bone resorption since they have no direct effect on renal
tubular reabsorption of calcium (Bonjour et al., 1988). Fol-
lowing multiple infusion only 40% of the patients without
skeletal metastases became normocalcaemic. The response
rate was higher (75%) in the single infusion group but this
may be falsely high since three patients in this group received
radiotherapy to their primary tumour between days 0 and 10,
which might have influenced their apparent response to treat-
ment. Assuming this to be so, the response rate would be
only 50% in the single infusion group for those patients with
humoral hypercalcaemia and no focal skeletal disease.
We conclude that clodronate is an effective treatment for
tumour-mediated hypercalcaemia, inducing a significant and
worthwhile response in both haematological malignancies
and in patients with solid tumours and bone metastases. The
response rate in patients without skeletal lesions and humoral
hypercalcaemia of malignancy is less complete. The use of a
single intravenous infusion of 1500 mg over 4 h is not
associated with adverse effects and provides a more con-
venient, but equally effective, treatment than repeated
infusions.
Clodronate was a kind gift from Huhtamaki Oy Leiras, Finland. The
studies were supported in part by a programme grant from the
Medical Research Council and by Rhone Poulenc Rorer and Huht-
amaki Oy Leiras.
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